Kevin Mills (President & CEO)

received his B.S. in Molecular Biology from the University of Colorado, his Ph.D. in Biology from the Massachusetts Institute of Technology, and postdoctoral fellowship training at Harvard Medical School.  Dr. Mills was a professor of genetics and cancer biology at The Jackson Laboratory, with academic appointments at Tufts University and the University of Maine.  He co-founded Cyteir Therapeutics, a small molecule cancer therapeutics startup, and ZubiBio, a hematology therapeutics startup.  He was the Chief Scientific Officer for the National Bleeding Disorders Foundation and served on the board of directors for the Maine Cancer Foundation before joining BioKansas and AdAstra BIO in 2024.

)Tisha Templeton, (Fractional Chief Operating Officer)

Tisha Templeton is a fractional Chief Operating Officer who specializes in implementing enterprise resource management systems to enhance communication and operational efficiency. With a background as Senior VP of Finance and Operations in regulatory consulting for pharma and biotech, she has led company-wide initiatives in finance, project management, and business development. Her key accomplishments include launching new program lines, building a Project Management Office, and overhauling financial tracking systems. Tisha holds a Regulatory Affairs Certificate from RAPS and studied Accounting at Orange Coast College, with expertise spanning strategic finance, HR, and IT.